Grant: Master's Award: Canada Graduate Research Scholarships - Master's program
University of Calgary
$27,000.00
Investigating the Radiosensitivity of Phosphatase and Tensin Homolog-Deficient Osteosarcoma after Treatment with a Synthetic Lethality-Based Therapy
EF 2025-26
Résumé
Osteosarcoma (OS) is the most common bone cancer in children and young adults. It is a highly aggressive form of cancer that frequently spreads to the lungs, making it difficult to treat. OS is largely radioresistant, and current chemotherapy treatments have limited efficacy in metastatic disease. Survival rates have not improved in several decades, highlighting the critical need for new and effective therapies. OS can be caused by significant genetic disruptions. Loss of the tumour suppressor gene phosphatase and tensin homolog (PTEN) occurs in approximately 60% of patients, and this genetic event is strongly associated with higher rates of metastasis and poorer outcomes. Despite the devastating effects of PTEN loss, this genetic vulnerability can be exploited for targeted therapies. PTEN-deficient cancer cells are sensitive to the loss of the DNA repair enzyme polynucleotide kinase 3’-phosphatase (PNKP). Synthetic lethality is an interaction between two genes where cells survive if only one gene is disrupted, but disruption of both leads to cell death. By leveraging this interaction, PTEN-deficient OS cells can be selectively targeted while preserving normal cells. Preliminary data with the small-molecule PNKP inhibitor A12B4C3 (A12) have demonstrated this interaction in PTEN-deficient OS cell lines. Furthermore, several types of PTEN-deficient cancers have shown sensitivity to ionizing radiation after treatment with A12. Since OS is poorly responsive to radiation therapy, this study aims to investigate whether treatment of PTEN-deficient OS with A12 can enhance the sensitivity of these tumours to ionizing radiation. Findings from this study will provide insight into viable treatment approaches for OS, offering hope to patients with this challenging disease.
Programme
Master's Award: Canada Graduate Research Scholarships - Master's program
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
572585
Name
Lei Jaden R
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Investigating the Radiosensitivity of Phosphatase and Tensin Homolog-Deficient Osteosarcoma after Treatment with a Synthetic Lethality-Based Therapy
Programtype2
Studentship Programs
Orgnameinp2
University of Calgary
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Novel Combination Therapies; Osteosarcoma; Phosphatase And Tensin Homolog (Pten); Pnkp Inhibitors; Polynucleotide Kinase 3'-Phosphatase (Pnkp); Pre-Clinical Research; Precision Oncology; Radiation Therapy; Synthetic Lethality; Targeted Therapeutics
Abstract
Osteosarcoma (OS) is the most common bone cancer in children and young adults. It is a highly aggressive form of cancer that frequently spreads to the lungs, making it difficult to treat. OS is largely radioresistant, and current chemotherapy treatments have limited efficacy in metastatic disease. Survival rates have not improved in several decades, highlighting the critical need for new and effective therapies. OS can be caused by significant genetic disruptions. Loss of the tumour suppressor gene phosphatase and tensin homolog (PTEN) occurs in approximately 60% of patients, and this genetic event is strongly associated with higher rates of metastasis and poorer outcomes. Despite the devastating effects of PTEN loss, this genetic vulnerability can be exploited for targeted therapies. PTEN-deficient cancer cells are sensitive to the loss of the DNA repair enzyme polynucleotide kinase 3’-phosphatase (PNKP). Synthetic lethality is an interaction between two genes where cells survive if only one gene is disrupted, but disruption of both leads to cell death. By leveraging this interaction, PTEN-deficient OS cells can be selectively targeted while preserving normal cells. Preliminary data with the small-molecule PNKP inhibitor A12B4C3 (A12) have demonstrated this interaction in PTEN-deficient OS cell lines. Furthermore, several types of PTEN-deficient cancers have shown sensitivity to ionizing radiation after treatment with A12. Since OS is poorly responsive to radiation therapy, this study aims to investigate whether treatment of PTEN-deficient OS with A12 can enhance the sensitivity of these tumours to ionizing radiation. Findings from this study will provide insight into viable treatment approaches for OS, offering hope to patients with this challenging disease.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Lei, Jaden R
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~